Drug Metabolism and Disposition最新文献

筛选
英文 中文
Efflux transporters in drug disposition during pregnancy. 妊娠期药物处置中的外排转运体。
IF 3.9 3区 医学
Drug Metabolism and Disposition Pub Date : 2024-05-29 DOI: 10.1124/dmd.123.001385
Xin Chen, Chunying Gao, Lyrialle W Han, Sibylle Heidelberger, Michael Z Liao, Naveen K Neradugomma, Zhanglin Ni, Diana L Shuster, Honggang Wang, Yi Zhang, Lin Zhou
{"title":"Efflux transporters in drug disposition during pregnancy.","authors":"Xin Chen, Chunying Gao, Lyrialle W Han, Sibylle Heidelberger, Michael Z Liao, Naveen K Neradugomma, Zhanglin Ni, Diana L Shuster, Honggang Wang, Yi Zhang, Lin Zhou","doi":"10.1124/dmd.123.001385","DOIUrl":"https://doi.org/10.1124/dmd.123.001385","url":null,"abstract":"<p><p>Evidence-based dose selection of drugs in pregnant women has been lacking due to challenges in studying maternal-fetal pharmacokinetics. Hence, many drugs are administered off-label during pregnancy based on data obtained from non-pregnant women. During pregnancy, drug transporters play an important role in drug disposition along with known gestational age-dependent changes in physiology and drug-metabolizing enzymes. In this review, as Dr. Qingcheng Mao's former and current lab members, we summarize the collective contributions of Dr. Mao, who lost his life to cancer, focusing on the role of drug transporters in drug disposition during pregnancy. Dr. Mao and his team initiated their research by characterizing the structure of Breast Cancer Resistance Protein [BCRP, ATP-Binding Cassette (ABC) G2]. Subsequently, they have made significant contributions to the understanding of the role of BCRP and other transporters, particularly P-glycoprotein (P-gp/ABCB1), in the exposure of pregnant women and their fetuses to various drugs, including nitrofurantoin, glyburide, buprenorphine, bupropion, tetrahydrocannabinol, and their metabolites. This review also highlights the gestation- and pregnancy-dependent transporter expression at the blood-brain and blood-placenta barriers in mice. <b>Significance Statement</b> Dr. Qingcheng Mao and his team have made significant contributions to the investigation of the role of efflux transporters, especially P-glycoprotein and breast cancer resistance protein, in maternal-fetal exposure to many xenobiotics: nitrofurantoin, glyburide, buprenorphine, bupropion, tetrahydrocannabinol and their metabolites. Studies of individual compounds and the expression of transporters during gestation and pregnancy have improved the understanding of maternal-fetal pharmacokinetics.</p>","PeriodicalId":11309,"journal":{"name":"Drug Metabolism and Disposition","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141174983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HCV Antiviral Drugs Have the Potential to Adversely Perturb the Fetal-Maternal Communication Axis through Inhibition of CYP3A7 DHEA-S Oxidation. 丙型肝炎病毒抗病毒药物有可能通过抑制 CYP3A7 DHEA-S 氧化作用对母胎沟通轴产生不利影响。
IF 4.4 3区 医学
Drug Metabolism and Disposition Pub Date : 2024-05-16 DOI: 10.1124/dmd.123.001434
Hannah M Work, John C Hackett, Jed N Lampe
{"title":"HCV Antiviral Drugs Have the Potential to Adversely Perturb the Fetal-Maternal Communication Axis through Inhibition of CYP3A7 DHEA-S Oxidation.","authors":"Hannah M Work, John C Hackett, Jed N Lampe","doi":"10.1124/dmd.123.001434","DOIUrl":"10.1124/dmd.123.001434","url":null,"abstract":"<p><p>The hepatitis C virus (HCV) poses a great risk to pregnant people and their developing fetus, yet no HCV antiviral treatment guidelines have been established. While there has been a substantial increase in the development of HCV antivirals, the effect they have on the developing fetus remains poorly defined. Many of these drugs are metabolized through the cytochrome P450 CYP3A pathway, which is mediated by cytochrome P450 3A7 (CYP3A7) in the fetus and developing infant. In this study, we sought to investigate the effect HCV antivirals have on CYP3A7 metabolism, as this CYP enzyme plays a vital role in proper fetal and neonatal development. Of the 13 HCV antivirals we investigated, 8 (∼62%) inhibited CYP3A7 metabolic activity by 50% or more at a concentration of 20 <i>µ</i>M. Furthermore, paritaprevir, asunaprevir, simeprevir, danoprevir, and glecaprevir all had observed half-maximal inhibitory concentrations between the range of 10 and 20 <i>µ</i>M, which is physiologically relevant in comparison with the K<sub>m</sub> of dehydroepiandrosterone-sulfate (DHEA-S) oxidation (reported to be between 5 and 20 <i>µ</i>M). We also discovered that paritaprevir is a time-dependent inhibitor of CYP3A7, which shifts the IC<sub>50</sub> ∼twofold from 11 <i>µ</i>M to 5 <i>µ</i>M. Upon further characterization, paritaprevir inactivates DHEA-S metabolism by CYP3A7, with K<sub>I</sub> and K<sub>inact</sub> values of 4.66 <i>µ</i>M and 0.00954 minute<sup>-1</sup>, respectively. Depending on treatment plan and off-label drug use, HCV treatment could adversely affect the fetal-maternal communication axis by blocking fetal CYP3A7 metabolism of important endogenous hormones. SIGNIFICANCE STATEMENT: The prevalence of HCV in pregnant people is estimated at between 1% and 8% of the global population, yet little to no information exists about the risk antiviral treatment poses to the developing fetus. There is a potential risk of drugs adversely affecting mother-fetal communication by inhibiting fetal hepatic CYP3A7, an integral enzyme for estriol production. We discovered that five HCV antivirals inhibited DHEA-S metabolism by CYP3A7, and paritaprevir inactivated the enzyme. Our studies demonstrate the potential threat these drugs pose to proper fetal development.</p>","PeriodicalId":11309,"journal":{"name":"Drug Metabolism and Disposition","volume":null,"pages":null},"PeriodicalIF":4.4,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11114604/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139545942","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to "Utilizing a Dual Human Transporter MDCKII-MDR1-BCRP Cell Line to Assess Efflux at the Blood Brain Barrier". 更正 "利用双人类转运体 MDCKII-MDR1-BCRP 细胞系评估血脑屏障的外流情况"。
IF 3.9 3区 医学
Drug Metabolism and Disposition Pub Date : 2024-05-16 DOI: 10.1124/dmd.123.001476err
{"title":"Correction to \"Utilizing a Dual Human Transporter MDCKII-MDR1-BCRP Cell Line to Assess Efflux at the Blood Brain Barrier\".","authors":"","doi":"10.1124/dmd.123.001476err","DOIUrl":"https://doi.org/10.1124/dmd.123.001476err","url":null,"abstract":"","PeriodicalId":11309,"journal":{"name":"Drug Metabolism and Disposition","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140955989","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advances and Challenges in Modeling Cannabidiol Pharmacokinetics and Hepatotoxicity. 大麻二酚药代动力学和肝毒性建模的进展与挑战。
IF 3.9 3区 医学
Drug Metabolism and Disposition Pub Date : 2024-05-16 DOI: 10.1124/dmd.123.001435
Jessica L Beers, Zhu Zhou, Klarissa D Jackson
{"title":"Advances and Challenges in Modeling Cannabidiol Pharmacokinetics and Hepatotoxicity.","authors":"Jessica L Beers, Zhu Zhou, Klarissa D Jackson","doi":"10.1124/dmd.123.001435","DOIUrl":"10.1124/dmd.123.001435","url":null,"abstract":"<p><p>Cannabidiol (CBD) is a pharmacologically active metabolite of cannabis that is US Food and Drug Administration approved to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex in children aged 1 year and older. During clinical trials, CBD caused dose-dependent hepatocellular toxicity at therapeutic doses. The risk for toxicity was increased in patients taking valproate, another hepatotoxic antiepileptic drug, through an unknown mechanism. With the growing popularity of CBD in the consumer market, an improved understanding of the safety risks associated with CBD is needed to ensure public health. This review details current efforts to describe CBD pharmacokinetics and mechanisms of hepatotoxicity using both pharmacokinetic models and in vitro models of the liver. In addition, current evidence and knowledge gaps related to intracellular mechanisms of CBD-induced hepatotoxicity are described. The authors propose future directions that combine systems-based models with markers of CBD-induced hepatotoxicity to understand how CBD pharmacokinetics may influence the adverse effect profile and risk of liver injury for those taking CBD. SIGNIFICANCE STATEMENT: This review describes current pharmacokinetic modeling approaches to capture the metabolic clearance and safety profile of cannabidiol (CBD). CBD is an increasingly popular natural product and US Food and Drug Administration-approved antiepileptic drug known to cause clinically significant enzyme-mediated drug interactions and hepatotoxicity at therapeutic doses. CBD metabolism, pharmacokinetics, and putative mechanisms of CBD-induced liver injury are summarized from available preclinical data to inform future modeling efforts for understanding CBD toxicity.</p>","PeriodicalId":11309,"journal":{"name":"Drug Metabolism and Disposition","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11114601/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities. 2018-2023年FDA批准的激酶抑制剂:药物靶点、代谢途径和药物引起的毒性。
IF 3.9 3区 医学
Drug Metabolism and Disposition Pub Date : 2024-05-16 DOI: 10.1124/dmd.123.001430
Bethany D Latham, Raeanne M Geffert, Klarissa D Jackson
{"title":"Kinase Inhibitors FDA Approved 2018-2023: Drug Targets, Metabolic Pathways, and Drug-Induced Toxicities.","authors":"Bethany D Latham, Raeanne M Geffert, Klarissa D Jackson","doi":"10.1124/dmd.123.001430","DOIUrl":"10.1124/dmd.123.001430","url":null,"abstract":"<p><p>Small molecule kinase inhibitors are one of the fastest growing classes of drugs, which are approved by the US Food and Drug Administration (FDA) for cancer and noncancer indications. As of September 2023, there were over 70 FDA-approved small molecule kinase inhibitors on the market, 42 of which were approved in the past five years (2018-2023). This minireview discusses recent advances in our understanding of the pharmacology, metabolism, and toxicity profiles of recently approved kinase inhibitors with a central focus on tyrosine kinase inhibitors (TKIs). In this minireview we discuss the most common therapeutic indications and molecular target(s) of kinase inhibitors FDA approved 2018-2023. We also describe unique aspects of the metabolism, bioactivation, and drug-drug interaction (DDI) potential of kinase inhibitors; discuss drug toxicity concerns related to kinase inhibitors, such as drug-induced liver injury; and highlight clinical outcomes and challenges relevant to TKI therapy. Case examples are provided for common TKI targets, metabolism pathways, DDI potential, and risks for serious adverse drug reactions. The minireview concludes with a discussion of perspectives on future research to optimize TKI therapy to maximize efficacy and minimize drug toxicity. SIGNIFICANCE STATEMENT: This minireview highlights important aspects of the clinical pharmacology and toxicology of small molecule kinase inhibitors FDA approved 2018-2023. We describe key advances in the therapeutic indications and molecular targets of TKIs. The major metabolism pathways and toxicity profiles of recently approved TKIs are discussed. Clinically relevant case examples are provided that demonstrate the risk for hepatotoxic drug interactions involving TKIs and coadministered drugs.</p>","PeriodicalId":11309,"journal":{"name":"Drug Metabolism and Disposition","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11114602/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cytochrome P450 Enzymes as Drug Targets in Human Disease. 细胞色素P450酶作为人类疾病的药物靶点。
IF 3.9 3区 医学
Drug Metabolism and Disposition Pub Date : 2024-05-16 DOI: 10.1124/dmd.123.001431
F Peter Guengerich
{"title":"Cytochrome P450 Enzymes as Drug Targets in Human Disease.","authors":"F Peter Guengerich","doi":"10.1124/dmd.123.001431","DOIUrl":"10.1124/dmd.123.001431","url":null,"abstract":"<p><p>Although the mention of cytochrome P450 (P450) inhibition usually brings to mind unwanted variability in pharmacokinetics, in several cases P450s are good targets for inhibition. These P450s are essential, but in certain disease states, it is desirable to reduce the concentrations of their products. Most of the attention to date has been with human P450s 5A1, 11A1, 11B1, 11B2, 17A1, 19A1, and 51A1. In some of those cases, there are multiple drugs in use, e.g., exemestane, letrozole, and anastrozole with P450 19A1, the steroid aromatase target in breast cancer. There are also several targets that are less developed, e.g., P450s 2A6, 8B1, 4A11, 24A1, 26A1, and 26B1. SIGNIFICANCE STATEMENT: The selective inhibition of certain cytochrome P450s that have major physiological functions has been shown to be very efficacious in certain human diseases. In several cases, the search for better drugs continues.</p>","PeriodicalId":11309,"journal":{"name":"Drug Metabolism and Disposition","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11114603/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41114555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Special Section on Cytochrome P450 Enzymes in Toxicology and as Drug Targets-Editorial. 毒理学和药物靶标中的细胞色素 P450 酶特别章节-编辑。
IF 3.9 3区 医学
Drug Metabolism and Disposition Pub Date : 2024-05-16 DOI: 10.1124/dmd.124.001763
Xiao-Bo Zhong, Yurong Lai
{"title":"Special Section on Cytochrome P450 Enzymes in Toxicology and as Drug Targets-Editorial.","authors":"Xiao-Bo Zhong, Yurong Lai","doi":"10.1124/dmd.124.001763","DOIUrl":"https://doi.org/10.1124/dmd.124.001763","url":null,"abstract":"","PeriodicalId":11309,"journal":{"name":"Drug Metabolism and Disposition","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140956080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to "Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study". 对 "酒精肝和丙型肝炎肝脏中 1 期和 2 期药物代谢酶的丰度:定量靶向蛋白质组学研究"。
IF 3.9 3区 医学
Drug Metabolism and Disposition Pub Date : 2024-05-16 DOI: 10.1124/dmd.118.080523err
{"title":"Correction to \"Abundance of Phase 1 and 2 Drug-Metabolizing Enzymes in Alcoholic and Hepatitis C Cirrhotic Livers: A Quantitative Targeted Proteomics Study\".","authors":"","doi":"10.1124/dmd.118.080523err","DOIUrl":"https://doi.org/10.1124/dmd.118.080523err","url":null,"abstract":"","PeriodicalId":11309,"journal":{"name":"Drug Metabolism and Disposition","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140955987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
After fifty years of hepatic clearance models, where should we go from here? Improvements and implications for PBPK modeling 肝清除模型问世五十年后,我们该何去何从?PBPK 模型的改进和影响
IF 3.9 3区 医学
Drug Metabolism and Disposition Pub Date : 2024-05-08 DOI: 10.1124/dmd.124.001649
K. Sandy Pang, Weijia Ivy Lu, Gerard J. Mulder
{"title":"After fifty years of hepatic clearance models, where should we go from here? Improvements and implications for PBPK modeling","authors":"K. Sandy Pang, Weijia Ivy Lu, Gerard J. Mulder","doi":"10.1124/dmd.124.001649","DOIUrl":"https://doi.org/10.1124/dmd.124.001649","url":null,"abstract":"There is overwhelming preference for application of the unphysiologic, well-stirred model (WSM) over the parallel tube (PTM) and dispersion (DM) models to predict hepatic drug clearance, CLH, despite that liver blood flow is dispersive and closer to the DM in nature. The reasoning is the ease in computation relating the hepatic intrinsic clearance (CL<sub>int</sub>), hepatic blood flow (Q<sub>H</sub>), unbound fraction in blood (fu<sub>b</sub>) and the transmembrane clearances (CL<sub>in</sub> and CL<sub>ef</sub>) to CL<sub>H</sub> for the WSM. However, the WSM, being the least efficient liver model, predicts a lower E<sub>H</sub> that is associated with the in vitro CL<sub>int</sub> (V<sub>max</sub>/K<sub>m</sub>), therefore requiring scale-up to predict CL<sub>H</sub> in vivo. By contrast, the miniPTM, a 3-subcompartment tanks-in-series model of uniform enzymes, closely mimics the DM and yielded similar patterns for CL<sub>int</sub> vs. E<sub>H</sub>, substrate concentration [S], and K<sub>L/B</sub>, the tissue to outflow blood concentration ratio. We placed these liver models nested within PBPK models to describe the kinetics of the flow-limited, phenolic substrate, harmol, using the WSM (single compartment) and the miniPTM and ZLM (zonal liver) models of evenly- and unevenly-distributed glucuronidation and sulfation activities, respectively, to predicted CL<sub>H</sub>. For the same, given CL<sub>int</sub> (V<sub>max</sub> and K<sub>m</sub>), the WSM again furnished the lowest extraction ratio (E<sub>H,WSM</sub> = 0.5) compared to the miniPTM and ZLM (&gt;0.68). Values of E<sub>H,WSM</sub> were elevated to those for E<sub>H,PTM</sub> and E<sub>H,ZLM</sub> when the V<sub>maxs</sub> for sulfation and glucuronidation were raised 5.7 to 1.15-fold. The miniPTM is easily manageable mathematically and should be the new normal for liver/physiological modeling.","PeriodicalId":11309,"journal":{"name":"Drug Metabolism and Disposition","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140927494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of the CYP3A selective inhibitors CYP3cide, clobetasol, and azamulin for their potential to distinguish CYP3A7 activity in the presence of CYP3A4/5 比较 CYP3A 选择性抑制剂 CYP3cide、氯倍他索和氮杂霉素在 CYP3A4/5 存在的情况下区分 CYP3A7 活性的潜力
IF 3.9 3区 医学
Drug Metabolism and Disposition Pub Date : 2024-05-03 DOI: 10.1124/dmd.124.001598
Hannah M. Work, Sylvie E. Kandel, Jed N. Lampe
{"title":"Comparison of the CYP3A selective inhibitors CYP3cide, clobetasol, and azamulin for their potential to distinguish CYP3A7 activity in the presence of CYP3A4/5","authors":"Hannah M. Work, Sylvie E. Kandel, Jed N. Lampe","doi":"10.1124/dmd.124.001598","DOIUrl":"https://doi.org/10.1124/dmd.124.001598","url":null,"abstract":"The CYP3A7 enzyme accounts for ~50% of the total CYP content in fetal and neonatal livers and is the predominant CYP involved in neonatal xenobiotic metabolism. Additionally, it is a key player in healthy birth outcomes through the oxidation of dehydroepiandrosterone (DHEA) and DHEA-S (sulfate). The amount of the other hepatic CYP3A isoforms, CYP3A4 and CYP3A5, expressed in neonates is low, but highly variable, and therefore the activity of individual CYP3A isoforms is difficult to differentiate due to their functional similarities. Consequently, a better understanding of the contribution of CYP3A7 to drug metabolism is essential to identify the risk drugs may pose to neonates and developing infants. To distinguish CYP3A7 activity from CYP3A4/5, we sought to further characterize the selectivity of the specific CYP3A inhibitors CYP3cide, clobetasol, and azamulin. We utilized three substrate probes, dibenzylfluorescein, luciferin-PPXE, and midazolam, to determine the IC<sub>50</sub> and metabolism-dependent inhibition (MDI) properties of the CYP3A inhibitors. Probe selection had a significant effect on the IC<sub>50</sub> values and CYP inactivation across all inhibitory compounds and enzymes. CYP3cide and azamulin were both identified as MDIs and were most specific for CYP3A4. Contrary to previous reports, we found that CP was not an MDI of CYP3A5, but was more selective for CYP3A5 over CYP3A4/7. We further investigated CYP3cide and CP's ability to differentiate CYP3A7 activity in an equal mixture of recombinant CYP3A4, CYP3A5, and CYP3A7 and our results provide confidence of CYP3cide's and CP's ability to distinguish CYP3A7 activity in the presence of the other CYP3A isoforms.","PeriodicalId":11309,"journal":{"name":"Drug Metabolism and Disposition","volume":null,"pages":null},"PeriodicalIF":3.9,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140829022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信